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The Authors Reply: We have read the letter to the editor by
Hugo and Eliseo.1 Although all erythropoiesis-stimulating
agent (ESA) products have potential immunogenicity, we do
not think that induction of the recombinant erythropoietin
antibody seems to be a class effect of ESA. Combe et al.2 and
Singh3 have investigated biosimilar erythropoietins and showed
tremendously different characteristics from one product to
another, most likely resulting from the complexity of recombinant
protein manufacturing. Thus, the stringent regulations and
pharmacovigilance of each individual product is mandatory
to ensure patients’ safety.
All follow-up on recombinant erythropoietins in Thailand
has been licensed with limited nonclinical/clinical data and
without quality data, which makes it difﬁcult to deﬁne these
products as biosimilar by EMEA deﬁnition.4 The registration
of these products was licensed by generic chemical drug
paradigm, and pharmacovigilance was not required. The Thai
Food and Drug Administration (FDA) has now been revising
the regulation including the license revision. On reviewing the
data with the Thai FDA, we found that the pharmacovigilance
plan of follow-up on recombinant erythropoietins in Thailand
has never been submitted by any pharmaceutical industries.
Pharmacovigilance is a proactive, well-planned action
formally submitted to the regulator to monitor drug-related
problems that may not be evidenced during the pre-
marketing period. The Thai ESA registry has been initiated
by Thai FDA and scientiﬁc societies, not the pharmaceu-
tical industries, aiming to provide more precise risk of the
immunogenicity.
Although aplastic anemia has been reported with higher
incidence in Thailand compared with the West, this back-
ground has no link to the pathogenesis of anti-recombinant
erythropoietin-associated pure red cell aplasia. The induction
of neutralizing antibody of recombinant erythropoietins
causes maturation arrest of erythroblasts and consequently
pure red cell aplasia, whereas environmental toxin exposure
causes damage of hematologic stem cells, resulting in
pancytopenia and thus aplastic anemia.
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Hemodialysis vs. peritoneal
dialysis in chronic heart failure:
getting to the heart of the matter
To the Editor: REIN registry data published by Sens et al.1
imply a survival beneﬁt for hemodialysis (HD) in end-stage
renal disease patients with chronic heart failure (CHF)
condition when starting HD or peritoneal dialysis (PD).
However, concerns relate to the correct CHF characterization
in this study. Besides the nephrologist’s judgment and a
crude New York Heart Association (NYHA) classiﬁcation
(combined class NYHA III–IV), the degree of CHF remains
unclear. Speciﬁcally, echocardiographic parameters of systolic
or diastolic cardiac function were not provided. Second, CHF
diagnosis was not ascertained at least one more time after
dialysis onset. Thus, initial overhydration due to renal failure
mimicking CHF cannot be ruled out. Third, no differentiation
was made between valvular and non-valvular CHF. Finally,
no speciﬁc NYHA class differentiation, i.e., the presence of
NYHA class III or IV, was provided. When using the
combination of NYHA III–IV, more PD patients may belong
to NYHA IV and, vice versa, more HD patients may belong to
NYHA III, which may represent an additional confounding
issue. The prognosis for NYHA class-III or class-IV patients is
quite different.2 Thus, the combination of NYHA III–IV may
have obscured a survival beneﬁt for either dialysis modality.
Unfortunately, neither brain natriuretic peptide (BNP) nor
NT-proBNP, surrogates of CHF, was determined. BNP could
have provided additional information on cardiorenal syn-
drome when interpreted over time after onset of dialysis.3
Until proven otherwise, the main outcome, survival, may have
been confounded by more severe CHF in terms of more
NYHA class-IV patients in the PD group.
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